Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
SOURCE NI Research
CARDIFF, Calif., March 19, 2013 /PRNewswire/ -- NI Research has released the March issue of NeuroPerspective. The issue features a comprehensive review of schizophrenia, with a focus on the progress being made in developing therapies that go beyond the blunting of the hallucinations and delusions that are the signature symptoms of this most devastating of all the psychiatric disorders.
"The advances being made in nicotinic and glutamatergic adjunctive treatments herald the long-awaited prospect of options for ameliorating the negative and cognitive symptoms of schizophrenia," said Harry Tracy, Ph.D., editor and publisher of NeuroPerspective.
The 32-page issue includes:
The March issue of NeuroPerspective is available as a single-issue purchase for $250.
Further information and online purchasing with immediate delivery are available at http://www.niresearch.com/onlinestore.html
About NI Research
NI Research is the leading publisher of independent research on the neurotherapeutics industry, and has developed an unmatched information base regarding both publicly and privately held CNS companies. NeuroPerspective (formerly NeuroInvestment) is the authoritative, independent, monthly review of the neurotherapeutics area, providing critical analysis of therapeutics-in-development.
A one-year subscription to NeuroPerspective is $2,300.
NI Research also publishes NeuroLicensing, the Private CNS Company Review, and NeuroSynopsis, a monthly four-page summary of highlights from NeuroPerspective. NIR also provides consulting services to the pharma industry regarding licensing and strategic planning.
©2012 PR Newswire. All Rights Reserved.